ALG1L2 (Asparagine-Linked Glycosylation 1-Like 2) is a protein that is implicated in the complex biological process of N-linked glycosylation. This protein is encoded by the gene ALG1L2 in humans. N-linked glycosylation is a critical post-translational modification involving the attachment of sugar molecules to asparagine residues in proteins. This modification is vital for proper protein folding, stability, and function.
The ALG1L2 protein is believed to function in the early stages of the N-linked glycosylation pathway. In this pathway, the initial steps involve the synthesis of a lipid-linked oligosaccharide (LLO) precursor, which is then transferred to specific asparagine residues on nascent proteins within the lumen of the endoplasmic reticulum (ER). ALG1L2 shares homology with ALG1, a known chitobiosyldiphosphodolichol beta-mannosyltransferase that catalyzes the addition of the first mannose residue to the oligosaccharide precursor. Although the precise role of ALG1L2 in the glycosylation pathway is not as thoroughly established, it is thought to be associated with similar glycosyltransferase activities due to its sequence and structural similarities to ALG1.The N-linked glycosylation process is essential for cellular function and organismal development. Errors in this pathway can lead to congenital disorders of glycosylation (CDGs), which are characterized by a wide variety of manifestations and can affect multiple organ systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine, an inhibitor of alpha-mannosidase II, affects glycoprotein processing in the N-linked glycosylation pathway. Its action may indirectly influence proteins involved in this pathway, potentially including ALG1L2. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a potent inhibitor of mannosidase I, which plays a role in N-linked glycosylation. Its inhibition can lead to altered glycoprotein processing, potentially impacting proteins like ALG1L2 involved in glycosylation. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
As an inhibitor of α-mannosidase, Deoxymannojirimycin impacts glycoprotein processing. This can indirectly affect the N-linked glycosylation pathway and potentially influence ALG1L2's activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine, a glucosidase inhibitor, can influence the N-linked glycosylation pathway and potentially impact proteins like ALG1L2 that are involved in glycosylation. | ||||||
Voglibose | 83480-29-9 | sc-204384 sc-204384A | 10 mg 50 mg | $198.00 $681.00 | ||
Voglibose is an alpha-glucosidase inhibitor. Its role in inhibiting glucosidases might indirectly influence glycosylation processes, potentially impacting proteins like ALG1L2. | ||||||
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Acarbose, another alpha-glucosidase inhibitor, can affect the N-linked glycosylation pathway by influencing glucosidases, potentially impacting the activity or function of ALG1L2. | ||||||